Philip Milliken

Philip Milliken is an experienced Clinical Development Director at Galvani Bioelectronics, overseeing therapy indication expansion, clinical trial biomarker strategy, and translational program leadership since November 2016. Previously, Philip held roles including Manager of Clinical Translation and Manager of Disease Biology, focusing on mechanism of action development and collaboration with academic partners on neuromodulation projects. Prior experience includes serving as Disease Biology Project Leader at GSK and as Non-Clinical Drug Safety Lead at Pfizer. In earlier roles at GSK, Philip was involved in clinical safety and pharmacovigilance. Academic credentials include a Ph.D. in Physiology and Pharmacology from the University of Strathclyde, coupled with a Bachelor's Degree in Immunology and Pharmacology from the same institution.